Is Amarin Corporation plc (AMRN) a Buy, Sell, or Hold?
Amarin Corporation plc
NASDAQ:AMRN
$14.37 USD
-$0.33 (-2.24%)
- Volume
- 51.97K
- Average Volume
- 84.07K
- Market Capitalization
- $297.21M
- P/E Ratio
- -8.88
- Dividend Yield
- 0.00%
- Price Target
- $2.00
- Year High
- $20.90
- Year Low
- $12.96
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $3.48
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Aaron D. Berg |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | AMRN |
| CUSIP | 023111404 |
| CIK | 0000897448 |
| Web | https://www.amarincorp.com |
| Phone | 353 1 669 9020 |
| Currency | USD |
| Employees | 80 |
| Country | IE |
Liquidity
| Debt-to-Equity Ratio | 0.01 |
| Payout Ratio | 0.00 |
| Current Ratio | 3.48 |
| Quick Ratio | 2.46 |
| Cash Ratio | 0.73 |
Sales & Book Value
| Annual Sales | $213.65M |
| Price / Sales | 1.38 |
| Cash Flow | 1.23 |
| Price / Cash Flow | 11.65 |
| Price / Book | 0.67 |
Price Target and Rating
| Average Stock Price Forecast | $2.00 |
| High Stock Price Forecast | $3.00 |
| Low Stock Price Forecast | $1.50 |
| Forecast Upside/Downside | 618.50% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 18 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-1.8 |
| Trailing P/E Ratio | -8.88 |
| PEG Ratio | -0.13 |
| P/E Growth | -0.13 |
| Net Income | $-38.8M |
| Net Margin | -15.64% |
| Pretax Margin | -16.16% |
| Return on Equity | -7.34% |
| Return on Assets | -5.20% |
Financials Score
| AltmanZ Score | -1.67 |
| Piotroski Score | 4.00 |
| Working Capital | 446.37M |
| Total Assets | 645.76M |
| Ebit | -8.07M |
| Market Cap | 304.04M |
| Total Liabilities | 196.35M |
Poll Results
About Amarin Corporation plc (NASDAQ:AMRN) Stock
Amarin Corporation plc is a pharmaceutical firm dedicated to the research, development, and commercialization of therapeutic solutions for cardiovascular diseases. Its operations span several international regions, including the United States, Germany, Canada, Lebanon, and the United Arab Emirates. The company's flagship product is VASCEPA, an omega-3 fatty acid formulation available by prescription only. This medication acts as an adjunctive therapy to diet, designed to decrease elevated triglyceride levels in adult patients suffering from severe hypertriglyceridemia. Amarin primarily distributes its offerings through wholesale channels and specialized pharmacy providers. Furthermore, the company has entered into a collaboration with Mochida Pharmaceutical Co., Ltd. to advance the develop ... ment and market introduction of drug products and new indications derived from Vascepa's active pharmaceutical ingredient, which encompasses omega-3 acid and eicosapentaenoic acid. Established in 1989 as Ethical Holdings plc, the organization rebranded to Amarin Corporation plc in 1999. Its corporate headquarters are located in Dublin, Ireland.
Bears are Losing Control Over Amarin (AMRN), Here's Why It's a 'Buy' Now
2026-07-10 10:56:05
Amarin (AMRN) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
2026-06-30 16:15:00
Clinically Validated, Increasingly Prescribed, Widely Reimbursed, and Affordable, VASCEPA Expected to Benefit from Increased Attention to Patients with Severely Elevated Triglycerides Clinically Validated, Increasingly Prescribed, Widely Reimbursed, and Affordable, VASCEPA Expected to Benefit from Increased Attention to Patients with Severely Elevated Triglycerides
Is Amarin (AMRN) Outperforming Other Medical Stocks This Year?
2026-06-12 10:41:14
Here is how Amarin (AMRN) and Amneal Pharmaceuticals (AMRX) have performed compared to their sector so far this year.
2026-05-27 08:00:00
DUBLIN and BRIDGEWATER, N.J., May 27, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) (Amarin), a company committed to advancing the science of cardiovascular disease (CVD) worldwide, today announced new data from a post hoc analysis of the REDUCE-IT® trial presented at the European Atherosclerosis Society (EAS) Congress 2026 in Athens, Greece.
IOVA Q1 Earnings Match Estimates, Sales Miss, Stock Down 13%
2026-05-08 12:11:09
Iovance matches Q1 earnings estimates, but weaker-than-expected Amtagvi and Proleukin sales sent shares down 13% despite revenue growth.
All You Need to Know About Amarin (AMRN) Rating Upgrade to Strong Buy
2026-05-05 13:01:08
Amarin (AMRN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Amarin's Q1 Loss Narrower Than Expected, Sales Increase Y/Y
2026-04-30 14:05:26
AMRN beats earnings and sales estimates as Vascepa sales rise and cost cuts take hold, while the partnered Europe strategy reshapes growth.
Amarin Corporation plc (AMRN) Q1 2026 Earnings Call Transcript
2026-04-29 16:42:01
Amarin Corporation plc (AMRN) Q1 2026 Earnings Call Transcript
Frequently Asked Questions
-
What is the current Amarin Corporation plc (AMRN) stock price?
-
Amarin Corporation plc(NASDAQ:AMRN) stock price is $14.37 in the last trading session. During the trading session, AMRN stock reached the peak price of $20.9 while $12.96 was the lowest point it dropped to. The percentage change in AMRN stock occurred in the recent session was --2.24% while the dollar amount for the price change in AMRN stock was -$-0.33.
-
AMRN's industry and sector of operation?
-
The NASDAQ listed AMRN is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of AMRN?
-
Peter Fishman | Senior Vice President & Chief Financial Officer
Jonathan N. Provoost | Executive Vice President, Chief Legal & Compliance Officer and Secretary
Aaron D. Berg | Chief Executive Officer, President & Director
David Keenan | Executive Vice President & Chief Operating Officer
Eric Boothe | Senior Vice President of Corporate Development -
How many employees does AMRN have?
-
Number of AMRN employees currently stands at 80. AMRN operates from Grand Canal Docklands, Dublin, DU 2, IE.
-
Link for AMRN official website?
-
Official Website of AMRN is: https://www.amarincorp.com
-
How do I contact AMRN?
-
AMRN could be contacted at phone #353 1 669 9020 and can also be accessed through its website. AMRN operates from Grand Canal Docklands, Dublin, DU 2, IE.
-
How many shares of AMRN are traded daily?
-
The average number of AMRN shares traded daily for last 3 months was 84.07K.
-
What is the market cap of AMRN currently?
-
The market value of AMRN currently stands at $297.21M with its latest stock price at $14.37